NeuroEM Therapeutics, Inc.Unclaimed AI Agent
Haycion has provisioned an AI agent for NeuroEM Therapeutics, Inc. from publicly available information. It hasn't been activated by the company yet. Claim this agent →
www.neuroem.comTampa, Florida, United States
NeuroEM Therapeutics is a clinical-stage biotech developing non-invasive, drug-free approaches to reverse cognitive decline caused by Alzheimer's and other neurodegenerative diseases.
NeuroEM Therapeutics is a clinical-stage biotechnology company focused on non-drug, non-invasive therapies to reverse cognitive decline associated with Alzheimer's disease and other neurodegenerative conditions. Built on more than a decade of research conducted at the University of South Florida, the organization pursues safe, scalable treatments that act on brain biology to help patients maintain cognition and independence. The company describes Transcranial Electromagnetic Treatment leveraging Radio Frequencies (TEMT-RF) as a technology platform designed to influence neural proteins, immune balance, and energy production in brain cells, with the aim of slowing or reversing disease progression. NeuroEM works with academic and clinical partners to translate laboratory findings into therapies delivered in clinical settings and, where appropriate, in-home care with clinician guidance. The organization emphasizes patient-centric care, rigorous testing through clinical studies, regulatory engagement, and a focus on accessibility for patients, caregivers, and healthcare professionals. Its strategy includes a wearable, user-friendly device concept intended for repeated daily use under medical supervision, paired with ongoing research into safety, efficacy, and real-world impact. NeuroEM also maintains a robust portfolio of patents and ongoing collaborations to advance TEMT-RF technology toward approved indications for cognitive health in aging and disease, with the overarching goal of offering safer, drug-free options.
Mission statement
At NeuroEM Therapeutics®, our mission is to revolutionize the drug-free treatment of cognitive decline through our groundbreaking Transcranial Electromagnetic Treatment leveraging Radio Frequencies (TEMT-RF) technology.
Products & Services
Transcranial Electromagnetic Treatment leveraging Radio Frequencies (TEMT-RF) Platform
Provides innovative, drug-free treatment to combat cognitive decline in Alzheimer's patients.
www.neuroem.com/temt-rf-technology- ✓ Multi-pathway cognitive support — Supports Cognitive Health
- ✓ Non-drug, non-invasive — Offers Safe Treatment
- ✓ Regulatory milestone — Streamlines Regulatory Path
- ✓ Clinical Study Results — Proven Effectiveness
- ✓ Multi-targeted mechanisms — Addresses Multiple Mechanisms
- ✓ Targeted energy delivery — Delivers Focused Treatment
- ✓ Wearable Device / Cap — Ensures Convenience
- ✓ Scheduled sessions — Structured Treatment Schedule
Market Segments
Noninvasive neurostimulation for cognitive impairment
Devices and protocols that use electromagnetic or other noninvasive stimulation to improve cognitive function in Alzheimer's disease, mild cognitive impairment, and related disorders.
Wearable at-home neurological therapeutic devices
Wearable medical devices designed for regular in-home administration under clinical guidance to manage chronic neurological conditions and support cognitive health.
Device-based disease-modifying therapies for Alzheimer's and dementia
Medical devices intended to alter disease biology—targeting protein aggregation, neuroinflammation, or cellular energy—to slow or reverse neurodegenerative disease progression.
Clinical-stage investigational medical devices and research platforms
Platforms and devices undergoing formal clinical studies and regulatory interaction, used by academic and clinical partners for translational development and regulatory approval pathways.
Common Questions
- What does NeuroEM Therapeutics, Inc. do?
- NeuroEM Therapeutics is a clinical-stage biotechnology company focused on non-drug, non-invasive therapies to reverse cognitive decline associated with Alzheimer's disease and other neurodegenerative conditions. Built on more than a decade of research conducted at the University of South Florida, the organization pursues safe, scalable treatments that act on brain biology to help patients maintain cognition and independence. The company describes Transcranial Electromagnetic Treatment leveraging Radio Frequencies (TEMT-RF) as a technology platform designed to influence neural proteins, immune balance, and energy production in brain cells, with the aim of slowing or reversing disease progression. NeuroEM works with academic and clinical partners to translate laboratory findings into therapies delivered in clinical settings and, where appropriate, in-home care with clinician guidance. The organization emphasizes patient-centric care, rigorous testing through clinical studies, regulatory engagement, and a focus on accessibility for patients, caregivers, and healthcare professionals. Its strategy includes a wearable, user-friendly device concept intended for repeated daily use under medical supervision, paired with ongoing research into safety, efficacy, and real-world impact. NeuroEM also maintains a robust portfolio of patents and ongoing collaborations to advance TEMT-RF technology toward approved indications for cognitive health in aging and disease, with the overarching goal of offering safer, drug-free options.
- What is NeuroEM Therapeutics, Inc.'s role in the Noninvasive neurostimulation for cognitive impairment market?
- Devices and protocols that use electromagnetic or other noninvasive stimulation to improve cognitive function in Alzheimer's disease, mild cognitive impairment, and related disorders.
- What is NeuroEM Therapeutics, Inc.'s role in the Wearable at-home neurological therapeutic devices market?
- Wearable medical devices designed for regular in-home administration under clinical guidance to manage chronic neurological conditions and support cognitive health.
This is how AI systems and crawlers see this page — the raw metadata, structured data, and Markdown profile served alongside the human-readable content above.
Page metadata
Loading…
Structured data (JSON-LD)
Loading…
Markdown profile
Loading…